Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Pressure-enabled Delivery in Radioembolization (TriNav Study)

NCT: NCT05128032 · COMPLETED

NCT IDNCT05128032
StatusCOMPLETED
Start Date2022-03-01
Completion2026-07-16
SponsorMassachusetts General Hospital (OTHER)
First posted
Last updated

Brief Summary

The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System * Standard 2.4F microcatheter, not otherwise specified

Frequently Asked Questions

What is Pressure-enabled Delivery in Radioembolization (TriNav Study)?

Pressure-enabled Delivery in Radioembolization (TriNav Study) is a clinical trial registered under NCT05128032. Current status: COMPLETED.

What is the status of NCT05128032?

The current status of NCT05128032 (Pressure-enabled Delivery in Radioembolization (TriNav Study)) is: COMPLETED.

When did Pressure-enabled Delivery in Radioembolization (TriNav Study) start?

Pressure-enabled Delivery in Radioembolization (TriNav Study) started on 2022-03-01.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.